Evidence profile
Semaglutide (30 mg Vial)
Semaglutide is used in authorized medicines. A product’s indication, formulation and manufacturer instructions determine which evidence applies.
01
Product identity
A lyophilized research-vial listing is not the same product as a manufactured authorized injection solution.
The supplier heading reads “Semaglutide | 30mg”, but a size field in its description says 10mg. The linked heading identifies this catalogue variant; the amount and formulation of supplied stock require confirmation before any quantity is used.[4]
02
What has been studied
Authorized-product monograph
Canadian product information
- Population or model
- Indication- and age-specific populations in the monograph
- Study route or material
- Manufactured subcutaneous injection solution
The Wegovy monograph defines an authorized formulation, specific indications and patient groups, together with safety and administration information. It provides the primary pathway for understanding that product.[1]
03
Evidence limits
The linked research product has not been established as an authorized, interchangeable formulation.
A Canadian clinical reviewer has not signed off patient instructions for this profile.
The reviewed sources do not establish patient instructions for this product. No dose, cycle, preparation method or administration schedule is provided here.
04
Formulation and handling evidence
DIN, manufacturer and exact dosage form if an authorized medicine is being referenced.
The supplied product’s formulation and identity; keep manufacturer-specific storage separate.
A compatible diluent, prepared-solution stability and container/device compatibility must be supported for the exact formulation. The diluent manufacturer’s instructions do not supply a universal storage period for every dissolved substance.[3]
05
Approval context
The status applies to products named in their monographs, not automatically to research vials bearing the ingredient name.[1]
06
Sources and review scope
- Wegovy Canadian product monographAuthorized-product monograph · Fresh official monograph: cover/formulation and indication passages; selected safety context carried forward · Checked 2026-09-09
- Health Canada: unauthorized injectable peptide productsRegulatory advisory · Fresh Health Canada advisory read, including product/DIN and RUO-label limits · Checked 2026-09-09
- Hospira/Pfizer: bacteriostatic water manufacturer informationManufacturer information; US presentation · Fresh manufacturer page, relevant compatibility/storage/supply passages · Checked 2026-09-09
- Amino Labs: Semaglutide | 30mgSupplier listing; identity reference · Exact heading, SKU, form and supplier URL from the full catalogue capture; not stock-lot authentication · Checked 2026-09-09
This is a selected-source evidence summary. It is not a systematic review, formal certainty grade or qualified clinical sign-off. Study dates and source-check dates are distinct.